ReviewAJOG global reports2026
Comparative effectiveness of lower-dose vs higher-dose aspirin for preeclampsia prevention: a systematic review and meta-analysis of randomized controlled trials.
Review in AJOG global reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether higher-dose aspirin (150-162 mg/d) reduces preeclampsia risk compared with lower-dose aspirin (75-81 mg/d) in pregnant women at elevated risk, using pooled evidence from all available head-to-head randomized controlled trials. DATA SOURCES: PubMed/MEDLINE, Cochrane CENTRAL, Embase, Scopus, and ClinicalTrials.gov were searched from inception through April 27, 2026. STUDY ELIGIBILITY CRITERIA: Parallel-group randomized controlled trials comparing at least two aspirin dose arms (head-to-head dose comparison) in pregnant women at elevated risk for preeclampsia, with a binary preeclampsia outcome reported. Aspirin-vs-placebo trials were excluded. STUDY APPRAISAL AND SYNTHESIS
methodsLog odds ratios were pooled using restricted maximum likelihood (REML) estimation with the Hartung-Knapp-Sidik-Jonkman (HKSJ) correction. Risk of bias was assessed using the Cochrane RoB 2 tool; evidence certainty was graded using GRADE. Egger's test, Duval-Tweedie trim-and-fill, and univariate meta-regression (geography, dose ratio, gestational age at initiation) were performed.
resultsSix randomized controlled trials enrolling 1099 participants across five countries were included. REML+HKSJ pooled OR 1.93 (95% CI 0.84-4.42,
conclusionApplying conservative statistical methods (REML+HKSJ), higher-dose aspirin (150-162 mg/d) was associated with approximately 48% lower odds of preeclampsia vs lower-dose aspirin (75-81 mg/d; OR 1.93), a clinically meaningful effect that did not reach conventional statistical significance (95% CI 0.84-4.42,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.